A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis

Figures & data

Figure 1 ASSESS study design.

Abbreviations: ETDRS, early treatment in diabetic retinopathy study; IAI, intravitreal aflibercept injection.

Table 1 Baseline characteristics of patients enrolled within the ASSESS trial

Baseline characteristic
N (full set analysis)	26
Age, mean (SD)	78 (±8) years
Length of time since diagnosis of exudative AMD, mean (SD)	14 months (±11 months)
Time since last injection prior to study enrollment, mean (SD)	50 days (±24 days) Range: 21–91 days
Previous treatment, % (n)	Bevacizumab: 26.9% (7) ranibizumab: 65.4% (17)
	Both: 7.1% (2)
Average number of treatments prior to study entry, mean (SD)	9.62 (±6.58)
	Range: 3–23 injections
Average number of injections during study, mean (SD)	7.92 (±0.27)
	Range: 7–8 injections
E-ETDRS BCVA letter score, mean (SD)	56.42 (±17.04) Range: 24–80
Snellen equivalent, mean	20/80 Range: 20/25–20/320
Central subfield thickness (μm), mean (SD)	304.08 (±75.44) Range: 210–505

Abbreviations: AMD, age-related macular degeneration; BCVA, best-corrected visual acuity; ETDRS, early treatment in diabetic retinopathy study.

Figure 2 Mean change from baseline in central subfield thickness.

Note: *Indicates that the value is statistically significant.

Figure 3 Mean change from baseline in BCVA score.

Note: *Indicates that the value is statistically significant.
Abbreviation: BCVA, best-corrected visual acuity.

Figure 4 Change from baseline in ETDRS score at 12 month study endpoint.

Abbreviation: ETDRS, early treatment in diabetic retinopathy study.

Figure 5 OCT fluid status in patients at month 12.

Abbreviation: OCT, optical coherence tomography.

Figure 6 Representative patient from the ASSESS trial demonstrating treatment response.

Abbreviation: BCVA, best-corrected visual acuity.